US Patent

US7511131 — Antisense modulation of apolipoprotein B expression

Composition of Matter · Assigned to Genzyme Corp · Expires 2027-01-29 · 1y remaining

Vulnerability score 27/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects the use of antisense compounds, particularly antisense oligonucleotides, to modulate apolipoprotein B expression.

USPTO Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.

Drugs covered by this patent

Patent Metadata

Patent number
US7511131
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-01-29
Drug substance claim
Yes
Drug product claim
No
Assignee
Genzyme Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.